Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism
Sponsor: KAI Pharmaceuticals
Terminated
Study was terminated early to allow subjects to roll over to study NCT02102204.
Other Secondary Hyperparathyroidism trials with similar outcome
This PHASE2 trial investigates Secondary Hyperparathyroidism and is currently terminated or withdrawn. KAI Pharmaceuticals leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — May 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- KAI Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.